Apogee Therapeutics (APGE) Change in Accured Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Change in Accured Expenses data on file, last reported at $4.7 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 77.02% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $957000.0, a 91.04% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 million, down 117.07% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $4.7 million, up from -$6.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for APGE reached as high as $10.9 million in Q3 2023 and fell as low as -$6.4 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $1.6 million across 5 years, with a median of $1.8 million in 2024.
• Across the five-year window, Change in Accured Expenses tumbled 769.35% in 2024 and surged 250.94% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.9 million in 2022, then slumped by 34.28% to $1.2 million in 2023, then tumbled by 414.77% to -$3.9 million in 2024, then sank by 63.46% to -$6.4 million in 2025, then jumped by 172.81% to $4.7 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $4.7 million in Q1 2026, -$6.4 million in Q4 2025, and $7.7 million in Q3 2025.